- Home
- MCRB vs XFOR Comparison
MCRB vs XFOR Comparison
Compare MCRB & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- XFOR
- Stock Information
- Founded
- MCRB 2010
- XFOR 2014
- Country
- MCRB United States
- XFOR United States
- Employees
- MCRB N/A
- XFOR N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRB Health Care
- XFOR Health Care
- Exchange
- MCRB Nasdaq
- XFOR Nasdaq
- Market Cap
- MCRB 131.0M
- XFOR 118.4M
- IPO Year
- MCRB 2015
- XFOR N/A
- Fundamental
- Price
- MCRB $0.73
- XFOR $0.49
- Analyst Decision
- MCRB Buy
- XFOR Strong Buy
- Analyst Count
- MCRB 4
- XFOR 3
- Target Price
- MCRB $5.63
- XFOR $3.50
- AVG Volume (30 Days)
- MCRB 2.0M
- XFOR 2.8M
- Earning Date
- MCRB 03-04-2025
- XFOR 11-13-2024
- Dividend Yield
- MCRB N/A
- XFOR N/A
- EPS Growth
- MCRB N/A
- XFOR N/A
- EPS
- MCRB N/A
- XFOR N/A
- Revenue
- MCRB $126,325,000.00
- XFOR $1,123,000.00
- Revenue This Year
- MCRB N/A
- XFOR N/A
- Revenue Next Year
- MCRB N/A
- XFOR $652.72
- P/E Ratio
- MCRB N/A
- XFOR N/A
- Revenue Growth
- MCRB 12856.41
- XFOR N/A
- 52 Week Low
- MCRB $0.54
- XFOR $0.26
- 52 Week High
- MCRB $1.53
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- MCRB 37.88
- XFOR 41.33
- Support Level
- MCRB $0.71
- XFOR $0.43
- Resistance Level
- MCRB $0.91
- XFOR $0.54
- Average True Range (ATR)
- MCRB 0.06
- XFOR 0.09
- MACD
- MCRB -0.02
- XFOR -0.03
- Stochastic Oscillator
- MCRB 8.37
- XFOR 13.71
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.